BioCentury | Aug 3, 2018

Lin’s new chapters

Taiwanese biotech Lin Bioscience Inc. and its wholly owned San Diego subsidiary Lin Bioscience Co. Ltd. are planning sequential listings in Taiwan and the U.S. to fund clinical programs targeting different markets. Lin has two...
BC Week In Review | Jan 20, 2017
Company News

Columbia University, Lin Bioscience deal

The university granted Lin Bioscience exclusive, worldwide rights to preclinical candidate LBS-008 and related IP. Lin expects to move the retinol binding protein 4 plasma (RBP4) inhibitor into Phase I testing this year to treat...
BC Week In Review | Nov 9, 2015
Clinical News

GSK2998728: Extension study data

Data from 38 FAP patients in the open-label extension of a double-blind, placebo-controlled, international Phase III trial showed that once-weekly 300 mg subcutaneous ISIS-TTRRx for >=18 months led to a maximum serum TTR knockdown of...
BC Week In Review | Apr 25, 2011
Company News

Intrinsic Bioprobes sales and marketing update

Intrinsic Bioprobes launched spectrometry-based protein assays for beta-2 microglobulin (B2M) , cystatin C (CST3) and retinol binding protein 4 plasma (RBP4) in the U.S. for diagnosing kidney disease and renal failure. The in vitro tests are...
BC Week In Review | Jul 6, 2009
Clinical News

Isis Pharmaceuticals preclinical data

In diet-induced mice, Isis said antisense reduction of retinol binding protein 4 plasma (RBP4) produced significant improvements in insulin sensitivity and cardiac glucose metabolism. The company said the data suggest that RBP-4 could be a...
BC Week In Review | Oct 6, 2008
Clinical News

Triolex: Phase I/IIb interim data

Interim data from the first 34 obese, insulin-resistant subjects enrolled in an ongoing double-blind, U.S. Phase I/IIb trial, showed that oral Triolex significantly improved insulin sensitivity and lowered blood glucose levels vs. placebo. Triolex also...
BC Extra | Jun 15, 2006
Clinical News

RBP4 linked to insulin resistance in humans

Researchers from Beth Israel Deaconess Medical Center and Harvard Medical School published in the New England Journal of Medicine that serum levels of retinol-binding protein 4 (RBP4) correlated with the magnitude of insulin resistance in...
BC Extra | Jul 20, 2005
Clinical News

Researchers report on diabetes target

Researchers published in Nature that lowering the levels of retinol binding protein-4 could represent a new treatment strategy for Type II diabetes. Transgenic mice overexpressing human RBP4 and mice injected with recombinant RBP4 developed insulin...
Items per page:
1 - 8 of 8